{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:07:37Z","timestamp":1762762057145,"version":"build-2065373602"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of insulin glargine\u2010300 once daily (Gla\u2010300) with insulin degludec\/aspart (IDegAsp) once daily in patients with type 2 diabetes (T2D) inadequately controlled on oral anti\u2010diabetic drugs (OADs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A systematic literature review of randomized controlled trials was followed by an indirect treatment comparison of studies involving insulin na\u00efve adults, inadequately controlled [glycated haemoglobin (HbA1c) \u22657.0%] on OADs, who received Gla\u2010300 or IDegAsp once daily. Outcomes of interest were change in HbA1c, blood glucose, weight and insulin dose, as well as incidence and event rate of hypoglycaemia and other adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four trials with broadly similar baseline patient characteristics were included in the meta\u2010analyses and indirect treatment comparison. At 24\u201028\u2009weeks, the indirect comparison of Gla\u2010300 to IDegAsp once daily estimated no statistically significant difference for change in HbA1c (%) from baseline [mean difference of 0.10% (95% CI: \u22120.20, 0.39;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.52)]; a statistically significant mean difference of \u22121.31\u2009kg (95% CI: \u22121.97, \u22120.65;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05) for change in body weight from baseline; statistically significant odds ratios of 0.62 (95% CI: 0.41, 0.93;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05) for incidence of any hypoglycaemia; and 0.47 (95% CI: 0.25, 0.87;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05) for incidence of anytime confirmed hypoglycaemia (plasma glucose &lt;3.0\u20103.1\u2009mmol\/L). No significant differences were observed for insulin dose and adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In insulin\u2010na\u00efve patients with T2D inadequately controlled on OADs, commencing Gla\u2010300 shows a comparable HbA1c reduction, but with significantly less weight gain and a lower incidence of any and confirmed hypoglycaemia compared with commencing IDegAsp.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15121","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T02:26:29Z","timestamp":1686709589000},"page":"2495-2504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative efficacy and safety of\n                    <scp>Gla\u2010300<\/scp>\n                    versus\n                    <scp>IDegAsp<\/scp>\n                    in\n                    <scp>insulin\u2010na\u00efve<\/scp>\n                    people with type 2 diabetes mellitus uncontrolled on oral anti\u2010diabetics"],"prefix":"10.1111","volume":"25","author":[{"given":"Robert","family":"Ritzel","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Angiology M\u00fcnchen Klinik Schwabing  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5397-961X","authenticated-orcid":false,"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Institute of Post Graduate Medical Education &amp; Research  Kolkata India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-2284","authenticated-orcid":false,"given":"Rifat","family":"Emral","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Endocrinology and Metabolic Diseases Ankara University  Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Malek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Setif University Hospital  S\u00e9tif Algeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longyi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The Third Affiliated Hospital\u2010Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Aileen","family":"Mabunay","sequence":"additional","affiliation":[{"name":"Sanofi, Global Medical  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5321-7164","authenticated-orcid":false,"given":"Wolfgang","family":"Landgraf","sequence":"additional","affiliation":[{"name":"Sanofi, Global Medical  Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Guyot","sequence":"additional","affiliation":[{"name":"Sanofi  Chilly Mazarin France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc., Operations  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-4074","authenticated-orcid":false,"given":"Divya","family":"Pushkarna","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc., Operations  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-8903","authenticated-orcid":false,"given":"Rayaz A.","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Medicine Weill Cornell Medicine  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S009"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.33.4.175"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0116-0"},{"key":"e_1_2_10_6_1","unstructured":"ChangP.Datamonitor Healtchare\u2013Diabetes Type 2 Disease Analysis Report.2020."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0044-z"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05078-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-602"},{"key":"e_1_2_10_10_1","unstructured":"Sanofi\u2010Aventis U.S. LLC.Toujeo\u00ae (insulin glargine injection) [drug label]. Food and Drug Administration websitehttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206538lbl.pdfAccessed November 4 2020."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12357"},{"key":"e_1_2_10_12_1","unstructured":"Novo Nordisk. Rhyzodeg.FDA highlights of prescribing information.2015https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/203313lbl.pdf"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163350"},{"key":"e_1_2_10_14_1","unstructured":"HigginsJPT GreenS.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].2011www.handbook.cochrane.org"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_10_16_1","unstructured":"R Core Team.R: A language and environment for statistical computing.R Foundation for Statistical.2018https:\/\/www.r-project.org\/"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13936"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12097"},{"key":"e_1_2_10_22_1","unstructured":"World Health Organization.About: Obesity.2022https:\/\/www.who.int\/health-topics\/obesity#tab=tab_1. Accessed June 19 2022"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009421"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11090639"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0606-6"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2052101"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:16:29Z","timestamp":1761862589000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/dom.15121"],"URL":"https:\/\/doi.org\/10.1111\/dom.15121","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"2022-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}